For people with Alzheimer’s disease (AD), amyloid-β42 (Aβ42) and phosphorylated tau (pTau181) in the cerebrospinal fluid (CSF) correlates with Pittsburgh compound B (PiB) positron emission tomography (PET) in different temporal proximities, while CSF and neuroimaging measures of neurodegeneration do not have a high correlation at any time interval.
Why this matters
The amyloid-tau-neurodegeneration framework suggests that CSF and neuroimaging measures within each biomarker group could be interchangeable. However, the impact of the time interval between the two assessments has not been well investigated.
This study identified CSF Aβ42 and pTau181 as early biomarkers of pathology, while imaging measures are later biomarkers.